Houston Methodist The Annual HMNCC GI Oncology Summit 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Medical Oncologists, Surgical Oncologists, Hepatologists, Transplant Surgeons, Gastroenterologists, Colorectal Surgeons, Radiation Oncologists

+ Sample video: contact me for sample video

+ Information:

This Summit will delve into the latest developments in managing gastrointestinal cancers. It will feature expert presentations on advancements in immunotherapy, molecular diagnostics, targeted therapies and new surgical techniques. Participants will also explore key trends in transplant oncology and the role of precision medicine. Each session will offer insights into disease pathogenesis, risk factors, prevention strategies, and innovative treatments, including discussions on minimally invasive procedures, enhanced imaging, and blood-based biomarkers. The symposium will emphasize how these advancements improve patient outcomes and provide a comprehensive review of current and emerging management strategies for various gastrointestinal cancers.

Learning Objectives

At the conclusion of this activity, the learner should be able to:

• Describe the epidemiology, risk factors, and prevention strategies for gastrointestinal cancers.

• Review the pathogenesis, surveillance modalities, and underuse of screening for hepatocellular carcinoma (HCC), focusing on blood-based biomarkers and management of pre-liver cancer diseases.

• Evaluate transplant-bridging approaches and the role of immunotherapy in both resectable and advanced hepatocellular carcinoma, as well as new developments in treating advanced cholangiocarcinoma.

• Assess updates on operative strategies for early-stage hepatobiliary cancers and transplant oncology for hilar and intrahepatic cholangiocarcinoma.

• Explain the latest advancements in molecular diagnostics, operative and perioperative approaches, and targeted therapies for pancreatic adenocarcinoma, low-/intermediate-grade neuroendocrine carcinoma, and colorectal cancers.

• Discuss advancements in multidisciplinary approaches for managing esophageal and gastric cancers, as well as the role of precision medicine in unresectable gastrointestinal malignancies.

Target Audience

This Summit is designed for physician scientists, practicing oncologists, hepatologists, transplant surgeons, physician assistants, advanced nurse practitioners, oncology nurses, gastroenterologists, residents, fellows, medical students, allied health care professionals, and clinical research associates. Attendees involved in hepatobiliary, pancreatic, neuroendocrine, colorectal, esophageal, and gastric cancer care will find valuable insights for advancing their practice and improving patient care.

Best for Medical Oncologists, Surgical Oncologists, Hepatologists, Transplant Surgeons, Gastroenterologists, Colorectal Surgeons, Radiation Oncologists, and Thoracic Surgeons.

Topics

• Genomic-Driven Precision Oncology in Colorectal Cancer – 2025 Therapeutic Frontiers

• Immunotherapy for MSS/pMMR Colorectal Cancer in 2025

• Advances in Resectable Gastroesophageal Cancers – Precision Approaches for 2025

• Immunotherapy and Biomarker Innovations for Unresectable Gastroesophageal Adenocarcinoma

• Novel Targets and Future Therapies in Gastroesophageal Adenocarcinoma

• Appendiceal Adenocarcinoma – Advances in Diagnosis and Therapeutic Strategies

• AI-Enabled Early Detection and Risk Stratification for Pancreatic Cancer

• Transplant Oncology for Cholangiocarcinoma – Genomic-Guided Strategies for 2025

• Immunotherapy Landscape for MSI-H/dMMR Colorectal Cancer – What’s New and What’s Next

• Precision Oncology and Immunotherapy in Cholangiocarcinoma

• Overview of Key TNT Rectal Cancer Trials and Considerations for Radiation Treatment

• Targeted Therapies for Pancreatic Cancer – Biomarker-Driven Advances

• Robotic Surgery for Early Stage Hepatobiliary Cancer

• Precision Management of Cirrhosis-Associated HCC – Novel Hepatologist Strategies for 2025

• Transforming Pre-Liver Cancer Management – Strategies for Reducing or Eliminating Liver Cancer

• Immunotherapy 2.0 – Novel Combinations and Biomarkers for HCC in 2025

• Next Generation HCC Screening – Liquid Biopsies and Hepatologist-Driven AI Models

• Hepatocellular Carcinoma – Have We Seen the Worst of It